2014 Patient Seminar - Houston, TX, USA

Return to the main Patient Seminar page.

Update on Latest Treatment Opportunities

HCL Research

Presenter:

Clinical Trials at the National Institutes of Health

Presenter:

Vemurafenib Research

Presenter:

Vemurafenib Trial

Presenter:

Ibrutinib Trial

Presenter:

Cladribine and Rituximab Trial

Presenter:

Question and Answer Session

What is the definition of Partial Remission (PR), Complete Remission (CR) and Minimal Residual Disease (MRD)? (Audio)

Speakers:

  • Dr. Michael R. Grever, The Ohio State Wexner Medical Center, USA

  • Dr. Farhad Ravandi, MD Anderson Cancer Center, USA

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

Is the BRAF mutation in all of our cells? (Audio)

Speaker:

  • Dr. Brunangelo Falini, University of Perugia, Italy

Are you more likely to develop a second malignancy with HCL? (Audio)

Speakers:

  • Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA

  • Dr. Robert J. Kreitman, National Institutes of Health, USA

Is there a higher incidence of HCL in certain patient populations or geographies? (Audio)

Speakers:

  • Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA

  • Dr. Robert J. Kreitman, National Institutes of Health, USA

  • Dr. Farhad Ravandi, MD Anderson Cancer Center, USA

Is Vemurafenib an appropriate treatment for Minimal Residual Disease? (Audio)

Speaker:

  • Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA

Does the amount of hairy cells in your system predict your response to treatment? (Audio)

Speaker:

  • Dr. Martin S. Tallman, M.D., Memorial Sloan-Kettering Cancer Center

Is fatigue related to HCL and an indication of the potential for treatment? (Audio)

Speaker:

  • Dr. Farhad Ravandi, M.D., MD Anderson Cancer Center

If you have an intolerance to purine analogs (Cladribine, Pentostatin, etc.), does it mean you are allergic or have a poor response to treatment? (Audio)

Speaker:

  • Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA

Do we know what causes the “hairy” projections in a hairy cell? (Audio)

Speaker:

  • Dr. Brunangelo Falini, University of Perugia, Italy

What are the latest treatment opportunities for HCL-v and how does HCL-v differ from HCL? (Audio)

Speaker:

  • Dr. Robert J. Kreitman, National Institutes of Health, USA

Is a drop in cholesterol associated with HCL? (Audit)

Speaker:

  • Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA

Should you get irradiated blood and what about vaccinations? (Audio)

Speaker:

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

Is it common to use prophylaxis to fight infection during treatment? (Audio)

Speakers:

  • Dr. Michael R. Grever, The Ohio State Wexner Medical Center, USA

  • Dr. Claire Dearden, The Royal Marsden, USA

  • Dr. Farhad Ravandi, MD Anderson Cancer Center, USA